<DOC>
	<DOCNO>NCT02430909</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy body distribution Bimekizumab ( UCB4940 ) add Certolizumab Pegol treatment patient Rheumatoid Arthritis . Neither patient doctor know treatment group .</brief_summary>
	<brief_title>Multiple Dose Study UCB4940 add-on Certolizumab Pegol Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Inclusion Criteria To eligible participate study , follow criterion must meet : Subject inform give approve write Informed Consent Form ( ICF ) . Subject consider reliable capable adhere protocol . Subject must diagnosis adultonset moderatetosevere RA least 6 month ' duration define ACR/EULAR 2010 classification criterion . Subject must : ≥6 tender joint ( 68 ) ≥6 swollen joint ( 66 ) CRP≥10.0mg/L . Subject must inadequate response least 1 synthetic DMARD . Subject least 18 year less 70 year age Visit 1 ( Screening ) . Female subject must either : postmenopausal permanently sterilize , childbearing potential , must willing use least 2 effective method contraception , Male subject partner childbearing potential must willing use condom sexually active , study 5 month last administration study drug . Exclusion Criteria Subjects permit enroll study follow criterion meet : Subject previously participate study previously assign treatment study investigational medicinal product ( IMP ) investigation study ( UCB4940 and/or CZP ) . Subject history active systemic/respiratory infection due fungal , parasitic , mycotic pathogen . Subjects know tuberculosis ( TB ) infection , high risk acquire TB infection , latent TB infection exclude . Subject high risk infection . Subject active infection serious infection within 12 week prior first dose study drug Week 0 . Subject renal liver impairment . Subject current past history gastrointestinal ulceration . Subject active neoplastic disease history neoplastic disease . Subject concomitant diagnosis inflammatory condition . Subject secondary , noninflammatory condition know diagnosis fibromyalgia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>